(JAZZ) Jazz Pharmaceuticals - Ratings and Ratios

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company specializing in the development and commercialization of innovative therapies for rare and serious diseases. The company focuses on neurology, oncology, and rare diseases, with a portfolio that includes FDA-approved treatments for conditions such as narcolepsy, epilepsy, and various cancers. Its lead products include Xywav (calcium, magnesium, potassium, sodium oxybates), a formulation for cataplexy and excessive daytime sleepiness in narcolepsy and idiopathic hypersomnia, and Xyrem (sodium oxybate), the first and only FDA-approved treatment for cataplexy and EDS in narcolepsy. The company also markets Epidiolex (cannabidiol), the first plant-based cannabinoid approved by the FDA for seizures in Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.

In oncology, Jazz offers Rylaze (asparaginase erwinia chrysanthemi (recombinant)-ryhn) and Enrylaze (inj.) for acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma. Additionally, Zepzelca (lurbinectedin) targets metastatic small cell lung cancer, while Zepzelca and Ziihera address specific HER2-positive cancers. Defitelio (defibrotide) is used for severe veno-occlusive disease, and Vyxeos (daunorubicin and cytarabine) treats therapy-related acute myeloid leukemia. The companys pipeline includes late-stage assets like Zanidatamab for HER2-expressing gastroesophageal cancers and earlier-stage candidates such as JZP815, a pan-RAF kinase inhibitor, and JZP441 for narcolepsy. Jazz has strategic collaborations with Redx Pharma, Autifony Therapeutics, Zymeworks, Sumitomo Pharma, and Werewolf Therapeutics.

Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has established itself as a leader in rare disease therapies, with a market cap of $6.242 billion and a forward P/E of 4.44, indicating potential undervaluation. The companys revenue growth is supported by its diversified portfolio and strong pipeline.

3-Month Forecast: Based on technical and fundamental data, Jazz Pharmaceuticals stock is currently below its 20-day (110.20), 50-day (126.94), and 200-day (118.49) moving averages, signaling bearish momentum. The average true range (ATR) of 5.44 suggests moderate volatility. However, the forward P/E of 4.44 and RoE of 13.68% indicate undervaluation potential. Over the next three months, the stock may face short-term weakness but could rebound if pipeline developments or earnings exceed expectations. Traders should monitor volume (20-day average: 1.32M) and SMA crossovers for trend reversals.